PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents yoy growth 0.5-0.75x RVPH's 95.93%. Martin Whitman would worry if slower accumulation signals weaker operations or bigger outflows.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Cash + STI yoy 0.5-0.75x RVPH's 95.93%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
0.75-0.9x RVPH's 72.84%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-8.67%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
53.46%
0.75-0.9x RVPH's 64.40%. Bill Ackman questions if competitor invests more aggressively for growth.
21.21%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
37.02%
Above 1.5x RVPH's 4.94%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Above 1.5x RVPH's 4.83%. Michael Burry sees a potential leverage warning sign.
37.77%
Similar yoy changes to RVPH's 45.49%. Walter Schloss sees parallel capital-raising strategies.
-3.87%
Similar yoy to RVPH's -3.55%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.55%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
59.08%
0.5-0.75x RVPH's 89.71%. Martin Whitman is wary of lagging equity growth vs. competitor.
53.46%
0.75-0.9x RVPH's 64.40%. Bill Ackman wonders if competitor invests or leverages more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
50-75% of RVPH's -102.37%. Bruce Berkowitz notes comparatively lower net debt expansion.